PGDx scores $21.4 mln Series A
Baltimore-based Personal Genome Diagnostics Inc, a provider of advanced cancer genome testing products and services, has secured $21.4 million in Series A funding. New Enterprise Associates led the round with participation from other investors that included Windham Venture Partners and Nanjing Kaiyuan Growth Capital Investments. In addition to the funding, Dr. Justin Klein, a general partner at NEA, has been added to PGDx's board of directors while Felix Dawson and Adam Fine of Windham Venture Partners will become board observers.
30 October 2015•4 mins read
